On the recordMay 22, 2013
Beyond harming the competitive position of American public companies, I have heard from innovative private companies in Virginia's 5th District, including many of our research and development bio-tech firms, that mandatory audit firm rotation would create a further disincentive to go public in light of the increased costs, and already complex regulatory scheme.
Source
congress.gov




